- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Arginase 1.
Displaying page 1 of 1.
EudraCT Number: 2022-003722-45 | Sponsor Protocol Number: CAEB1102-305 | Start Date*: 2023-04-17 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Open-Label Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects with Arginase 1 Deficiency | |||||||||||||
Medical condition: Arginase I deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004837-34 | Sponsor Protocol Number: CAEB1102-300A | Start Date*: 2019-06-18 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and ... | |||||||||||||
Medical condition: Arginase 1 Deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003163-67 | Sponsor Protocol Number: CAEB1102-102A | Start Date*: 2019-01-15 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency | |||||||||||||
Medical condition: Arginase 1 deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003851-45 | Sponsor Protocol Number: CAEB1102-101A | Start Date*: 2018-03-14 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102 | |||||||||||||
Medical condition: Arginase 1 deficiency Hyperargininemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000650-11 | Sponsor Protocol Number: HEP002 | Start Date*: 2014-09-15 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients. | |||||||||||||
Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002762-44 | Sponsor Protocol Number: RG-16-040 | Start Date*: 2018-05-01 | ||||||||||||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||||||||||||
Full Title: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults | ||||||||||||||||||||||||||||
Medical condition: Relpased/refractory paeditaric cancers: Leukaemias Sarcoma Neuroblastoma High grade glioma (brain cancers) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017091-25 | Sponsor Protocol Number: P081110 | Start Date*: 2010-07-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-... | |||||||||||||
Medical condition: Drépanocytose homozygote présentant une microalbuminurie associée à une hyperfiltration glomérulaire | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004074-28 | Sponsor Protocol Number: UKHEP001 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: A prospective, open label, multicenter, randomized, safety and preliminary efficacy study of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patients | |||||||||||||
Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006068-32 | Sponsor Protocol Number: CDX110-04 | Start Date*: 2012-07-04 | |||||||||||
Sponsor Name:Celldex Therapeutics, Inc | |||||||||||||
Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ... | |||||||||||||
Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.